This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorn, G. W. Search for Related Content PubMed PubMed Citation Articles by Dorn, G. W., II Related Collections Contractile function Congestive Developmental biology

(Circulation. 2001;104:9.)
© 2001 American Heart Association, Inc.

Editorials

Calcineurin Inhibition in Hypertrophy

Back From the Dead!

Gerald W. Dorn, II, MD

From the Division of Cardiology, University of Cincinnati, Cincinnati, Ohio.

Correspondence to Gerald W. Dorn II, MD, Division of Cardiology, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267-0542. E-mail dorngw@ucmail.uc.edu

Key Words: Editorials • cardiomyopathy • hypertrophy • inhibitors • calcineurin

Reactive cardiac hypertrophy has long been recognized as a compensatory process that enhances ventricular function through normalization of wall stress in the face of increased hemodynamic load. For almost as long, it has also been appreciated that the natural history of a hypertrophied heart faced with unremitting hemodynamic overload is progression from a state of functional compensation to one of functional decompensation, or heart failure.¹ Under these circumstances, the heart dilates and fails because hypertrophy fails, and in this manner, nature’s temporary cure for hemodynamic overload becomes part and parcel of the disease.

Because a stimulus for hypertrophy is the initiator event in a reactive compensatory response leading to pathological decompensation, an obvious remedy for pathological myocardial hypertrophy is elimination of the stimulus. This is not always possible, however, owing to insufficient control of blood pressure in hypertensive patients, uncorrected valvular stenoses or insufficiencies, or hypertrophy of viable myocardium in postinfarction patients. Furthermore, genetic causes of hypertrophic cardiomyopathy are not directly addressable with current technologies. Therefore, identification of molecular and biochemical mediators of myocardial hypertrophy has been pursued to delineate hypertrophy signaling events that might be susceptible to targeted inhibition. Various candidate signaling pathways, mostly involving hormone receptors, associated G proteins, or their downstream kinase effectors, have been implicated with the use of in vitro and in vivo systems.² Recently, protein phosphatases have also received attention in this regard.

The most thoroughly investigated and controversial protein phosphatase proposed to be a hypertrophy signaling factor is calcineurin (CN). CN is a . . . [Full Text of this Article]

This article has been cited by other articles:

				J. R. Keys, E. A. Greene, C. J. Cooper, S. V. Naga Prasad, H. A. Rockman, and W. J. Koch Cardiac hypertrophy and altered {beta}-adrenergic signaling in transgenic mice that express the amino terminus of {beta}-ARK1 Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2201 - H2211. [Abstract] [Full Text] [PDF]

				R. S. Williams Calcineurin Signaling in Human Cardiac Hypertrophy Circulation, May 14, 2002; 105(19): 2242 - 2243. [Full Text] [PDF]

				J. A. Hill, B. Rothermel, K.-D. Yoo, B. Cabuay, E. Demetroulis, R. M. Weiss, W. Kutschke, R. Bassel-Duby, and R. S. Williams Targeted Inhibition of Calcineurin in Pressure-overload Cardiac Hypertrophy. PRESERVATION OF SYSTOLIC FUNCTION J. Biol. Chem., March 15, 2002; 277(12): 10251 - 10255. [Abstract] [Full Text] [PDF]